U.S. Markets
Gilead Sciences (GILD) announced the CHMP of the EMA has adopted a positive opinion, recommending the marketing authorization of Trodelvy as a monotherapy for the treatment of adult patients with unresectable locally advanced or TNBC
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
